样式: 排序: IF: - GO 导出 标记为已读
-
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-03-12 Sreevalsa Appukkuttan, Gilbert Ko, Chunmay Fu, Breyanne Bannister, Sheldon X. Kong, Jay Jhaveri, Stephen J. Freedland
Nonmetastatic castration-resistant prostate cancer (nmCRPC) patients are often older and use concurrent medications that increase the potential for drug–drug interactions (pDDIs). This study assess...
-
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors and beyond Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-03-12 Athina Stravodimou, Ioannis A. Voutsadakis
Chemotherapy has been traditionally used as neo-adjuvant therapy in breast cancer for down-staging of locally advanced disease in all sub-types. In the adjuvant setting, genomic assays have shown t...
-
Racial and socioeconomic disparities in triple-negative breast cancer treatment Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-03-11 Zouina Sarfraz, Azza Sarfraz, Onaiza Mehak, Ramsha Akhund, Shehar Bano, Hinna Aftab
Triple-negative breast cancer (TNBC) continues to be a significant concern, especially among minority populations, where treatment disparities are notably pronounced. Addressing these disparities, ...
-
Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-03-07 Riccardo Camedda, Viviana Frantellizzi, Roberta Danieli, Giuseppe De Vincentis, Luca Filippi
To provide an overview of the available literature data on clinical applications of positron emission tomography (PET) targeting the urokinase-type plasminogen activator receptor in oncology.A lite...
-
Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systematic review and meta-analysis Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-03-04 Yuqian Feng, Kaibo Guo, Huimin Jin, Jing Jiang, Menglei Wang, Shengyou Lin
Neoadjuvant immunotherapy has emerged as a prominent research focus recently. For potentially operable patients, neoadjuvant therapy serves as a primary method to reduce tumor load and facilitate s...
-
Molecular subtype identification and prognosis stratification by a immunogenic cell death-related gene expression signature in colorectal cancer Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-26 Junping Lei, Jia Fu, Tianyang Wang, Yu Guo, Mingmin Gong, Tian Xia, Song Shang, Yan Xu, Ling Cheng, Binghu Lin
This study intended to develop a new immunogenic cell death (ICD)-related prognostic signature for colorectal cancer (CRC) patients.The Non-Negative Matrix Factorization (NMF) algorithm was adopted...
-
Development and validation of survival nomograms in elder triple-negative invasive ductal breast carcinoma patients Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-16 Tao Jiang, Sha Yang, Guanghui Wang, Ying Tan, Shu Liu
We aimed to develop a nomogram to predict the overall survival of elderly patients with Triple-negative invasive ductal breast carcinoma (TNIDC).12165 elderly patients with nonmetastatic TNIDC were...
-
Exploiting c-RAF dependency in RAS mutant cancer: beyond catalytic activity Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-16 Sean F. Cooke, Connor M. Blair
Published in Expert Review of Anticancer Therapy (Just accepted, 2024)
-
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime? Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-12 Luca Filippi, Orazio Schillaci
Locally advanced and metastatic urothelial carcinoma (UC) presents a bleak prognosis, with limited treatment options. NECTIN-4, an overexpressed protein in UC, has become a target for therapy. Enfo...
-
Ifosfamide-induced nephrotoxicity in oncological patients Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-12 Juan Eduardo Quiroz-Aldave, María Del Carmen Durand-Vásquez, Freddy Shanner Chávez-Vásquez, Alexandra Noelia Rodríguez-Angulo, Sonia Elizabeth Gonzáles-Saldaña, Carlos César Alcalde-Loyola, Julia Cristina Coronado-Arroyo, Francisca Elena Zavaleta-Gutiérrez, Luis Alberto Concepción-Urteaga, Juan Carlos Haro-Varas, Marcio José Concepción-Zavaleta
Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage.A comprehensive review was conducted, including 100 arti...
-
Considerations regarding maintenance therapy for acute myeloid leukemia in remission Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-12 Gary J. Schiller, Vlad Kustanovich
For most adult patients with acute myeloid leukemia, relapse is characteristic of the disease. When allotransplant in first complete remission is administered as consolidative therapy, relapse is s...
-
Cancer immunotherapy efficacy and machine learning Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-12 Yuting Fang, Xiaozhong Chen, Caineng Cao
Immunotherapy is one of the major breakthroughs in the treatment of cancer, and it has become a powerful clinical strategy, however, not all patients respond to immune checkpoint blockade and other...
-
Circadian rhythm-based cancer therapy in randomised clinical trials Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-12 Loredana G. Marcu
Since the 2017 Nobel Prize awarded to J. Hall, M. Rosbash and M.W. Young for their discoveries of molecular mechanisms behind the biological clock, circadian rhythm-based therapy, also known as chr...
-
Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-12 Amrita Goyal, Francine Foss
Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of cutaneous T-cell lymphoma. Although many available treatments offer temporary disease control, allogeneic hematopoietic ...
-
Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-12 Shulin Zhou, Yi Jiang, Chengyan Luo, Lin Yuan
Poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitors (PARPi) treatment for ovarian cancer (OC) are ever-changing. This study aimed to compare the efficacy and overall safety of available ...
-
Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-12 Mus’ab Theeb Mustafa, Aws Khalid Abushanab, Mahmoud Taysir Mousa, Rana Ahmed Qawaqzeh, Hamza Muneer Alakhras, Ahmad Sami Othman, Ahmad Sa’ed
Our systematic review and meta-analysis aimed to evaluate the clinical efficacy and safety of Rucaparib, a PARP inhibitor (PARPi), in patients with ovarian cancer and BRCA mutation.Online databases...
-
LncRNA HCG11 enhances the chemosensitivity of non-small cell lung cancer cells to Gemcitabine via miR-17-5p/p21 axis Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-12 Yufen Xu, Xiaoli Tan, Qi Yang, Zhixian Fang, Wenyu Chen
This study investigated the inhibitory effects of lncRNA HLA Complex Group 11 (HCG11) on non-small cell lung cancer (NSCLC) and the molecular mechanisms.Bioinformatics analysis was conducted to det...
-
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2024-02-01 Xingyuan Ma, Zhe Wang, Shuaiyang Wang, Ye Tian, Bei Xie, Jing Li, Bin Ma, Linjing Li
Circulating tumor DNA (ctDNA) in peripheral blood has become a promising noninvasive biomarker. However, the diagnostic potential of Wnt/β-catenin signaling pathway-related ctDNA for liver cancer i...
-
The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-12-08 Lane H. Miller, Kim L. Maxa, Stuart S. Winter, Nathan P. Gossai
Nelarabine is a guanine nucleoside analog and functions to terminate DNA synthesis in dividing cells. Pre-clinical and clinical studies have shown that it preferentially accumulates in T-cells wher...
-
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-12-08 Barbara Geerinckx, Laure-Anne Teuwen, Tiffany Foo, Timon Vandamme, Annabel Smith, Marc Peeters, Timothy Price
Prognosis of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) remains disappointing with a 5-year overall survival of only 3–5%. Compared to other cancers, the evolution in standar...
-
Novel therapies for metastatic prostate cancer Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-12-08 Albert Jang, Sree M. Lanka, Hui Ting Ruan, Hamsa L.S. Kumar, Angela Y. Jia, Jorge A. Garcia, Omar Y. Mian, Pedro C. Barata
Patients with metastatic prostate cancer, especially in the castrate-resistant setting, have a poor prognosis. Many agents have been approved for metastatic prostate cancer, such as androgen recept...
-
Medical imaging and multimodal artificial intelligence models for streamlining and enhancing cancer care: opportunities and challenges Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-12-08 Kevin Pierre, Manas Gupta, Abheek Raviprasad, Seyedeh Mehrsa Sadat Razavi, Anjali Patel, Keith Peters, Bruno Hochhegger, Anthony Mancuso, Reza Forghani
Artificial intelligence (AI) has the potential to transform oncologic care. There have been significant developments in AI applications in medical imaging and increasing interest in multimodal mode...
-
Immune checkpoint inhibitors in advanced cutaneous melanoma: a systematic review and meta-analysis of efficacy and review of characteristics Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-12-08 Sara Mahdiabadi, Sara Momtazmanesh, Amirali Karimi, Nima Rezaei
Immune checkpoint inhibitors (ICIs) are one of the most promising approaches toward advanced melanoma. Here, we aimed to perform a meta-analysis of randomized controlled trials (RCTs) to evaluate t...
-
Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysis Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-12-08 Wei Luo, Jing Zhu, Wenxue Zhang, Airu Yu, Wei Zhou, Ke Xu
To systematically analyze the efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer (NSCLC).The candidate studies were identified in PubMed, Embase, Cochrane Libr...
-
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-12-08 Gyula Ostoros, Robert Hettle, Nefeli Georgoulia, Mehmet Berktas, Pratibha Chander, Ignacio Diaz Perez, Anne-Marie Couto, Christian Eichinger, Polly Field, Peter Morten
We wanted to evaluate if event-free survival (EFS) is a reliable surrogate for overall survival (OS) in patients with resectable non-small cell lung cancer (r-NSCLC) receiving neoadjuvant therapy. ...
-
Prognostic significance of Dickkopf-1 in head and neck squamous cell carcinoma Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-12-04 Kai Chen, Jin Li, Yanfeng Ouyang, Yulong Xie, Guiqiong Xu, Tianliang Xia, Rui You, Guichao Liu, Han He, Rong Huang, Mingyuan Chen
Dickkopf-1 (DKK1) exhibits abnormal expression in various cancers and correlates with poor prognosis. This study investigates DKK1’s prognostic relevance in head and neck squamous cell carcinoma (H...
-
Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-11-28 Stefano Molica, David Allsup
Chronic lymphocytic leukemia (CLL) management has witnessed a transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal antibody (mAb) regimens, as exemplified by the...
-
Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-11-07 Bin Hu, Yanfei Zhang, Bingjing Jiang, Angcheng Li
This meta-analysis aimed to evaluate the prognostic significance of circulating long non-coding RNAs (lncRNAs) in colorectal cancer (CRC).A comprehensive literature search was conducted in database...
-
Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-10-27 Akito Fukuda, Tatsuya Yoshida
Anaplastic lymphoma kinase (ALK) gene rearrangement is detected in approximately 3–5% of non-small cell lung cancer (NSCLC) cases. Tyrosine kinase inhibitors (TKIs) targeting ALK rearrangement (ALK...
-
Immunotherapy in urothelial cancer: current status and future directions Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-10-27 Claudia Piombino, Elena Tonni, Marco Oltrecolli, Marta Pirola, Stefania Pipitone, Cinzia Baldessari, Massimo Dominici, Roberto Sabbatini, Maria Giuseppa Vitale
Since 2016, the progressive use of immune checkpoint inhibitors (ICIs) starting from second-line treatment has led to an improvement in overall survival in locally advanced and metastatic urothelia...
-
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-10-27 Jasmijn I. Verhoef, Ediz Klont, Frans J. van Overveld, Ger T. Rijkers
Immune checkpoint inhibition (ICI) therapy has revolutionized the treatment of cancer. Inhibitory molecules, either on the tumor or on cells of the immune system, are blocked, allowing the immune s...
-
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-10-27 Kimia Kazemzadeh, Sadra Behrouzieh, Nima Rezaei
Leukemia is an abnormal clonal development of leukemic cells originating from the bone marrow, which is widely known for its significant prevalence and mortality rate. Chemotherapy, surgery, radiat...
-
Locoregional recurrence in triple negative breast cancer: past, present, and future Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-10-26 Jennifer Tran, Arushi Thaper, Nerea Lopetegui-Lia, Azka Ali
Triple negative breast cancer (TNBC) is a rare but aggressive biological subtype of breast cancer associated with higher locoregional and distant recurrence rates and lower overall survival despite...
-
Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-10-27 Dat Le, Bhavana Konda
The rearranged during transfection (RET) mutation is an oncogene driver for the development of cancer. Selpercatinib is a highly selective RET inhibitor that has demonstrated anti-tumor activity in...
-
Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-10-27 Fumitaka Koga
Despite the lack of level 1 evidence, selective bladder-sparing therapy using trimodal therapy is currently recommended by guidelines as a standard of care in patients with non-metastatic, muscle-i...
-
Deciding individual treatment for primary retroperitoneal sarcoma Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-10-27 Deanna Ng, Alexander Bertrand, Roberta Sanfilippo, Dario Callegaro
Retroperitoneal sarcomas (RPS) are rare mesenchymal tumors that account for only 0.1–0.2% of all malignancies. Management of this disease is challenging, and resection remains the cornerstone of tr...
-
2023 ASCO Genitourinary Cancers Symposium: a focus on urothelial carcinoma Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-10-27 Antonio Cigliola, Viria Beccia, Annunziato Anghelone, Martina Panebianco, Chiara Ciccarese, Roberto Iacovelli
In this article, we describe the main acquisitions of urothelial carcinoma (UC) management reported at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium. A major develo...
-
The role of immune checkpoint inhibition in triple negative breast cancer Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-10-26 Kidist Tarekegn, Merve Keskinkilic, Tyler J. Kristoff, Sean T. Evans, Kevin Kalinsky
Immunotherapy has revolutionized cancer treatment, including TNBC, which has limited options of treatment and poor prognosis. ICIs studied in TNBC include pembrolizumab, nivolumab, atezolizumab, an...
-
Treatment optimization in early triple negative breast cancer Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-10-26 Elias Kotteas, Luca Boscolo Bielo, Carmine Valenza, Celeste Santoro, Chrysanthi Koukoutzeli, Dario Trapani, Giuseppe Curigliano
The treatment of early-stage triple-negative breast cancer (TNBC) has radically changed in recent years. Response to neoadjuvant treatment has provided prognostic information, and the achievement o...
-
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-09-24 Anna R. Schreiber, Cindy L. O’Bryant, Peter Kabos, Jennifer R. Diamond
Metastatic triple-negative breast cancer (TNBC) is an aggressive sub-type of breast cancer. Despite recent advances, metastatic TNBC remains difficult to treat with limited targeted treatment optio...
-
Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-09-25 Ahmed Mohamed, Megan Kruse, Jennifer Tran
Immune checkpoint inhibitors have been particularly effective in treating cancers with robust immune microenvironments and have been successfully incorporated into the management of metastatic ER-n...
-
Pediatric cancer care management during the COVID-19 pandemic: a review of the literature and a single-centre real-life experience of an Italian pediatric oncology unit Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-09-15 Olga Nigro, Chiara Oltolini, Federica Barzaghi, Caterina Uberti Foppa, Maria Pia Cicalese, Maura Massimino, Elisabetta Schiavello
The severe acute respiratory syndrome coronavirus-2 pandemic significantly affected clinical practice, also in pediatric oncology units. Cancer patients needed to be treated with an adequate dose d...
-
Triple-negative breast cancers Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-09-14 Steven A Narod, Rebecca Dent
Published in Expert Review of Anticancer Therapy (Ahead of Print, 2023)
-
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-09-13 K.H.M. Verdonschot, S. Arts, P.B. Van den Boezem, J.H.W. de Wilt, J.J. Fütterer, M.W.J. Stommel, C.G. Overduin
This study aims to systematically review current evidence on ablative margins and correlation to local tumor progression (LTP) after thermal ablation of hepatocellular carcinoma (HCC) and colorecta...
-
Medullary thyroid carcinoma Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-08-30 Maria Rosa Pelizzo, Esmeralda Isabella Mazza, Caterina Mian, Isabella Merante Boschin
Medullary thyroid carcinoma (MTC) constitutes approximately 5–10% of all thyroid cancers. Although the tumor forms in the thyroid, it doesn’t originate from thyroid cells, but from the C cells or p...
-
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-08-28 Rahul V Parghane, Sandip Basu
The prostate-specific membrane antigen (PSMA) targeted radioligand therapy (PRLT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients has generated significant int...
-
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-08-24 Yun Yang, Jun Li, Chao Jing, Yuhao Zhai, Zhigang Bai, Yingchi Yang, Wei Deng
The potential mechanism underlying the association between Homologous recombination deficiency (HRD) and immunotherapy in colon cancer has not been investigated.The exon sequencing data and transcr...
-
How can we refine the prognostic stratification of triple-negative breast cancer? Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-08-15 Federica Miglietta, Maria Vittoria Dieci
Published in Expert Review of Anticancer Therapy (Just accepted, 2023)
-
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-08-13 Piotr Rutkowski, Anna M. Czarnecka
Up to 30% of patients with stage IIB and 50% of stage IIC melanoma experience recurrence within 5 years after radical surgery. Adjuvant treatment is expected to improve this prognosis.Pembrolizumab...
-
Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-08-13 Jerold Loh, Jia Li Low, Manavi Sachdeva, Peter QJ Low, Rachel Su Jen Wong, Yiqing Huang, Puey Ling Chia, Ross A Soo
The current standard of care of locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation, followed by consolidation durvalumab. However, there is evidence that the effica...
-
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-08-08 Chengren Zhang, Lili Liu, Jingjing Li, Yaochun Lv, Dewang Wu, Shiyun Xu, Cong Cao, Lixia Zhao, Yijun Liu, Xiaolong Ma, Xiongfei Yang, Binbin Du
Our objective was to estimate the effect of flexible sigmoidoscopy (FS)-based screening on colorectal cancer (CRC) incidence and mortality by conducting an updated meta-analysis of randomized contr...
-
Liquid biopsies for detection, surveillance, and prognosis of urothelial cancer: a future standard? Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-08-08 Igor Duquesne, Mohamad Abou Chakra, Lory Hage, Ugo Pinar, Yohann Loriot
Liquid biopsies are used for the detection of tumor-specific elements in body fluid. Their application in prognosis and diagnosis of muscle/non-muscle invasive bladder cancer (MIBC/NMIBC) or upper ...
-
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-08-07 Tsz Him So, Sheetal Sharma, Reizel Parij, Carmel Spiteri, Evanka Chawla, Prabhakar Pandey, Tanujaa Rajasekaran
ABSTRACT Introduction This systematic review evaluated treatment patterns and guidelines in advanced/metastatic and adjuvant renal cell carcinoma (RCC) in the Asia-Pacific region. Areas covered Embase, PubMed, and congresses were searched for observational studies and guidelines in accordance with PRISMA. Records published during 2016–2021 (2019–2021 for congresses) were included. Expert opinion Nine
-
Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-08-01 Lauriane Lemelle, Delphine Guillemot, Anne-Laure Hermann, Arnaud Gauthier, Matthieu Carton, Nadège Corradini, Angélique Rome, Pablo Berlanga, Anne Jourdain, Aude Marie Cardine, Sarah Jannier, Hélène Boutroux, Anne Sophie Defachelles, Isabelle Aerts, Birgit Geoerger, Marie Karanian, François Doz, Hervé J Brisse, Gudrun Schleiermacher, Olivier Delattre, Gaëlle Pierron, Daniel Orbach
ABSTRACT Background NTRK gene fusions have been identified in various tumors; some requiring aggressive therapy and sometimes new TRK inhibitors (TRKi). We aimed to describe a national, unselected, retrospective, multicenter cohort. Research design and methods Patients were identified through the French sarcoma diagnostic laboratory at Institut Curie through samples analyzed by RT-qPCR or whole-transcriptome
-
Efficacy and safety of CalliSpheres® microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-07-28 Guang Sheng Zhao, Yu Xin Song, Jin Bo Sun, Song Liu, Fang Xu, Jian Ma, Chuang Li, Fei Gao, Jun Zhou, Ruo Yu Wang, Song Nian Liang
The purpose of this study was to observe the safety and efficacy of CalliSpheres microspheres drug-eluting beads (DEB) transhepatic arterial chemoembolization (CSM-TACE) for liver metastasis of gas...
-
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-07-27 Maryam Noori, Farimah Fayyaz, Mohammad Reza Zali, Davood Bashash
Which patients may benefit more from immune checkpoint inhibitors (ICIs) is still an important question. The present study aimed to investigate the role of the PD-L1 molecule in predicting the effe...
-
Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-07-24 Ticiana Leal, Mark A Socinski
ABSTRACT Introduction Lung cancer is the second most common cancer in the world and the leading cause of cancer-related mortality. Immune checkpoint inhibitors (ICIs), as monotherapy or in combination with platinum-based chemotherapy, have emerged as the standard of care first-line treatment option for patients with advanced non-small cell lung cancer (NSCLC) without actionable genomic alterations
-
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-07-24 Rebecca L. Porter, Ursula A. Matulonis
ABSTRACT Introduction Mirvetuximab soravtansine (mirvetuximab) is an antibody drug conjugate (ADC) comprised of a humanized folate receptor alpha (FRα)-binding monoclonal antibody attached via a cleavable linker to the cytotoxic maytansinoid molecule, DM4. FRα is expressed in several epithelial cancers, including high grade serous ovarian cancer (HGSOC). Mirvetuximab received accelerated approval by
-
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-07-23 Javier Ros, Marta Rodríguez-Castells, Nadia Saoudi, Iosune Baraibar, Francesc Salva, Josep Tabernero, Elena Élez
ABSTRACT Introduction The presence of a BRAF-V600E mutation in metastatic colorectal cancer (mCRC) is observed in approximately 12% of cases and is associated with poor prognosis and aggressive disease. Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing
-
Myeloid cell leukemia-1 as a candidate prognostic biomarker in cancers: a systematic review and meta-analysis Expert Rev. Anticancer Ther. (IF 3.3) Pub Date : 2023-07-23 Jianrong Wang, Yu He, Chao Yang, Qiurui Luo, Bingchi Wang
Studies have shown that myeloma cell leukemia-1 (MCL-1) is associated with the prognosis of patients with cancer. To further validate the prognostic value of MCL-1 in cancer, a meta-analysis was co...